GlassScriptPhysician profile
Matthew S Cohen
NPI 1558304014
$10,820.68
in general payments reported to CMS, 2019-2025
37 companies · $2,778 in 2025
The $2,778 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $312 · 2021: $70.81 · 2022: $1,337 · 2023: $1,821 · 2024: $2,924 · 2025: $2,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,501 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,500.78 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,254.86 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,847.48 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $904.31 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $808.42 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $451.53 | 2021-2025 | |
| Gilead Sciences, INC. | $417.80 | 2019-2025 | |
| Celgene Corporation | $404.18 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $291.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $230.16 | 2019-2024 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $202.47 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $202.01 | 2022-2024 | Dificid |
| Qol Medical, LLC | $158.70 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $157.99 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $140.19 | 2019-2024 | Linzess |
| Aimmune Therapeutics, INC. | $130.52 | 2023-2025 | Zenpep |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.